Client testimonial
A digital revolution in patient care
- Capgemini and Sanofi have been working together to better the life of patients for over a decade, and in 2024 Capgemini was selected as one of the global healthcare firm’s preferred partners in both R&D and Manufacturing & Supply (M&S). Pius S. Hornstein, PhD, Sanofi’s Head of Digital Global Business Units, explains how technology is expanding boundaries in life sciences.
Pius S. Hornstein
PhD, Sanofi’s Head of Digital Global Business Units
Why have digital and AI become central to Sanofi’s growth and development?
Pius S. Hornstein - Digital is at the heart of Sanofi’s ambition to transform the practice of medicine. By embracing AI and data, Sanofi is bringing new treatments to patients faster. Paul Hudson, Sanofi’s CEO, has a vision for the company to become the first pharmaceutical powered by AI at scale. By equipping teams with AI at their fingertips, Sanofi is enhancing decision making and driving growth.
What is the potential impact of AI and Gen AI on life sciences?
P. S. H. - Gen AI is already revolutionizing life sciences by expediting drug discovery and improving diagnostics, enabling more personalized patient care. These technologies streamline global clinical trials, accelerating the development of treatments. Getting valuable insights from the vast amount of data is a complex process. Now, with AI at scale, data and agents open new possibilities, like predicting drug safety and efficacy, or optimizing drug design.
Tell us about the annual “Accelerate Together” event held with Capgemini.
P. S. H. - The “Accelerate Together” event is held annually at Future4Care, a joint initiative in Paris set up by Capgemini, Sanofi, Orange, and Generali in 2021. For each edition, Capgemini puts together interactive workshops with subject matter experts to address Sanofi’s biggest challenges. The Capgemini team works across business lines to present an event that promotes cross learning from different global business units at Sanofi, with a focus on presenting the most innovative projects and use cases. The 2024 edition focused on ecosystems, exploring how AI and tech can reinvent healthcare. There were over 225 attendees and a Carousel of Innovations presenting six zones of collaboration between Capgemini and Sanofi.
How have previous editions led to concrete project developments for Sanofi?
P. S. H. - Previous editions have been instrumental in fostering collaboration, facilitating key stakeholder interactions that have led to concrete project developments in both M&S and R&D sectors, as well as around sustainability topics. Our partnership with Capgemini exemplifies how digital innovation and collaboration can drive significant advancements in life sciences, benefiting patients around the globe.